Company Overview

Industry Sector: Medical Devices and Instruments

Company Overview: Cyto Pulse is an innovator in the development and licensing of instruments to discover monoclonal antibodies, produce polynucleotide therapeutics and medical devices to deliver the new medicine polynucleotide (DNA, RNA) vaccines. Cyto Pulse has over 40 licensing agreements with pharmaceutical and biotechnology companies and clinical trials in progress using its polynucleotide delivery systems. The Cyto Pulse clinical trial focus is minimal residual disease cancer (prostate, colorectal, breast, etc) and infectious disease (HIV, dengue).

Target Market(s): Pharmaceutical and biotechnology companies worldwide for our instrument business and vaccine delivery sites worldwide for our medical device business.

Management

Leadership:
Richard Walters, Chairman, President and CEO
John Burke, MBA, CPA, CFO
Alan King, DVM, PhD, Vice President
Derin Walters, Vice President
Stephen Schimpff, MD, Director
Daniel Rak, Director
Harold Chappelear, Director

Scientific Advisory Board:
Stephen Schimpff, MD, former CEO University of Maryland Medical Center
Judith Karp, MD - Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Division of Hematologic Malignancies
Carol Tacket, MD - Professor of Medicine, Center for Vaccine Development, University of Maryland Medical Center
Rubin Mezrich, MD, PhD - Professor and Chief of Diagnostic Radiology, University of Maryland Medical School and Medical Center

Key Value Drivers

Technology: Cyto Pulse is a leader in the electric field based delivery of polynucleotides and other material into living cells in vivo and ex vivo (electroporation and electrofusion). The dramatic improvements are in complex voltage waveforms (PulseAgile®) and electrodes which produce the complex electric fields. The Hybrimune™ system has become a worldwide standard for hybridoma production, the Cyto-LVT™ systems are now available for large volume transfection and the Derma Vax™ and Easy Vax™ systems for the delivery of DNA vaccines. The Easy Vax system is a small portable device developed for large scale delivery of DNA vaccines by minimally trained user.

Competitive Advantage: Cyto Pulse has over 40 patents and patents pending worldwide on methods and devices for complex electric field generation and polynucleotide vaccines.

Plan & Strategy: expand licensing in the instrument business and seek strategic partners in the polynucleotide vaccine delivery business

*Easy Vax™ Technology funded by the NIAID and being commercialized under the NIH-CAP

Pipeline

<table>
<thead>
<tr>
<th>Study</th>
<th>Partner</th>
<th>System</th>
<th>Pre-clinical</th>
<th>Reg</th>
<th>Phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate Cancer</td>
<td>Uppsala University Hospital Cancer Center Karolinska</td>
<td>Derma Vax™</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolerance Study</td>
<td>NIAID and U Maryland Center for Vaccine Research</td>
<td>Easy Vax™</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolerance Study</td>
<td>National Institute on Aging</td>
<td>Derma Vax™</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal Cancer</td>
<td>Swedish Institute of Infectious Disease, Karolinska Institute</td>
<td>Derma Vax™</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV</td>
<td>Swedish Institute of Infectious Disease, Södersjukhuset</td>
<td>Derma Vax™</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>